216 related articles for article (PubMed ID: 28262735)
21. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
23. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.
Yemisci M; Bozdag S; Cetin M; Söylemezoglu F; Capan Y; Dalkara T; Vural I
Neurosurgery; 2006 Dec; 59(6):1296-302; discussion 1302-3. PubMed ID: 17277693
[TBL] [Abstract][Full Text] [Related]
25. [Favourable result for temozolomide in recurrent high-grade glioma].
Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Ling Y; Wei K; Zou F; Zhong S
Int J Pharm; 2012 Jul; 430(1-2):266-75. PubMed ID: 22486964
[TBL] [Abstract][Full Text] [Related]
27. A Potential Nanofiber Membrane Device for Filling Surgical Residual Cavity to Prevent Glioma Recurrence and Improve Local Neural Tissue Reconstruction.
Huang D; Lin C; Wen X; Gu S; Zhao P
PLoS One; 2016; 11(8):e0161435. PubMed ID: 27548322
[TBL] [Abstract][Full Text] [Related]
28. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
29. Electrospun micro- and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro.
Xie J; Wang CH
Pharm Res; 2006 Aug; 23(8):1817-26. PubMed ID: 16841195
[TBL] [Abstract][Full Text] [Related]
30. Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Wang N; Sun P; Lv M; Tong G; Jin X; Zhu X
Biomater Sci; 2017 May; 5(5):1041-1050. PubMed ID: 28378865
[TBL] [Abstract][Full Text] [Related]
31. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
32. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
[TBL] [Abstract][Full Text] [Related]
33. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Wicks RT; Azadi J; Mangraviti A; Zhang I; Hwang L; Joshi A; Bow H; Hutt-Cabezas M; Martin KL; Rudek MA; Zhao M; Brem H; Tyler BM
Neuro Oncol; 2015 Jan; 17(1):70-80. PubMed ID: 25053853
[TBL] [Abstract][Full Text] [Related]
34. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
35. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
36. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Miller K; Dixit S; Bredlau AL; Moore A; McKinnon E; Broome AM
Nanomedicine (Lond); 2016 Mar; 11(6):581-95. PubMed ID: 27003178
[TBL] [Abstract][Full Text] [Related]
37. Co-loading of Temozolomide with Oleuropein or rutin into polylactic acid core-shell nanofiber webs inhibit glioblastoma cell by controlled release.
Ercelik M; Tekin C; Parin FN; Mutlu B; Dogan HY; Tezcan G; Aksoy SA; Gurbuz M; Yildirim K; Bekar A; Kocaeli H; Taskapilioglu MO; Eser P; Tunca B
Int J Biol Macromol; 2023 Dec; 253(Pt 2):126722. PubMed ID: 37673167
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
de Groot JF; Lamborn KR; Chang SM; Gilbert MR; Cloughesy TF; Aldape K; Yao J; Jackson EF; Lieberman F; Robins HI; Mehta MP; Lassman AB; Deangelis LM; Yung WK; Chen A; Prados MD; Wen PY
J Clin Oncol; 2011 Jul; 29(19):2689-95. PubMed ID: 21606416
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
[TBL] [Abstract][Full Text] [Related]
40. [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Li Y; Gao Y; Liu G; Zhou X; Wang Y; Wang Y; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2014 May; 34(5):631-5. PubMed ID: 24849425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
